Nair Nandini, Gongora Enrique
Division of Cardiology, Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, United States.
Memorial Cardiac and Vascular Institute, Hollywood, FL 33031, United States.
Curr Cardiol Rev. 2017;13(3):183-188. doi: 10.2174/1573403X13666170216150955.
The concept of antioxidant therapies assumes high importance as oxidative stress is associated with cardiovascular aging via endothelial dysfunction. This review focuses on exploring the interaction between nrf-2 and ADMA in influencing the nitric oxide pathway and cardiovascular function.
A systematic review of literature from 1990 to 2016 was conducted using Pubmed and Google Scholar. The literature suggests a strong influence of nrf-2 activation on up regulation of DDAH I which degrades ADMA, the endogenous inhibitor of nitric oxide synthase. The resulting decrease of ADMA would in turn enhance nitric oxide (NO) production. This would support endothelial function by adequate NO production and homeostasis of endothelial function.
As NO production has many positive pleiotropic effects in the cardiovascular system, such an interaction could be utilized for designing molecular therapeutics. The targets for therapy need not be limited to activation of nrf-2. Modulation of molecules downstream such as DDAH I can be used to regulate ADMA levels. Most current literature is supported by animal studies. The concept of antioxidant therapies needs to be tested in well-defined randomized control trials. The biochemical basis of nrf-2 activation needs to be substantiated in human studies.
由于氧化应激通过内皮功能障碍与心血管衰老相关,抗氧化疗法的概念具有高度重要性。本综述着重探讨核因子E2相关因子2(nrf-2)与非对称二甲基精氨酸(ADMA)在影响一氧化氮途径和心血管功能方面的相互作用。
利用PubMed和谷歌学术对1990年至2016年的文献进行系统综述。文献表明,nrf-2激活对降解一氧化氮合酶内源性抑制剂ADMA的二甲基精氨酸二甲胺水解酶I(DDAH I)的上调有强烈影响。ADMA的减少反过来会增强一氧化氮(NO)的生成。这将通过充足的NO生成和内皮功能的稳态来支持内皮功能。
由于NO生成在心血管系统中有许多积极的多效性作用,这种相互作用可用于设计分子疗法。治疗靶点不必局限于nrf-2的激活。调节下游分子如DDAH I可用于调节ADMA水平。目前大多数文献得到动物研究的支持。抗氧化疗法的概念需要在明确的随机对照试验中进行检验。nrf-2激活的生化基础需要在人体研究中得到证实。